ATE334673T1 - Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten - Google Patents

Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten

Info

Publication number
ATE334673T1
ATE334673T1 AT98959850T AT98959850T ATE334673T1 AT E334673 T1 ATE334673 T1 AT E334673T1 AT 98959850 T AT98959850 T AT 98959850T AT 98959850 T AT98959850 T AT 98959850T AT E334673 T1 ATE334673 T1 AT E334673T1
Authority
AT
Austria
Prior art keywords
helfer
zel
treatment
type
mediated immune
Prior art date
Application number
AT98959850T
Other languages
English (en)
Inventor
Werner Bollag
Michael Klaus
Paola Panina-Bordignon
Francesco Sinigaglia
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE334673T1 publication Critical patent/ATE334673T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT98959850T 1997-11-12 1998-11-05 Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten ATE334673T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97119776 1997-11-12

Publications (1)

Publication Number Publication Date
ATE334673T1 true ATE334673T1 (de) 2006-08-15

Family

ID=8227610

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98959850T ATE334673T1 (de) 1997-11-12 1998-11-05 Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten

Country Status (15)

Country Link
US (5) US6133309A (de)
EP (1) EP1030662B1 (de)
JP (3) JP3704471B2 (de)
KR (4) KR20040032963A (de)
CN (2) CN1511519A (de)
AR (1) AR017590A1 (de)
AT (1) ATE334673T1 (de)
AU (1) AU749810B2 (de)
BR (1) BR9814957A (de)
CA (1) CA2307879C (de)
DE (1) DE69835441T2 (de)
ES (1) ES2270537T3 (de)
TR (1) TR200001228T2 (de)
WO (1) WO1999024024A2 (de)
ZA (1) ZA9810122B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914465A (pt) 1998-09-29 2001-10-09 Gamida Cell Ltd Métodos para controlar a proliferação e a diferenciação de células-tronco e células progenitoras e uma composição farmacêutica para induzir a diferenciação em uma população de células
US8560951B1 (en) 1998-12-18 2013-10-15 Thomson Licensing System and method for real time video production and distribution
US7024677B1 (en) 1998-12-18 2006-04-04 Thomson Licensing System and method for real time video production and multicasting
US6909874B2 (en) * 2000-04-12 2005-06-21 Thomson Licensing Sa. Interactive tutorial method, system, and computer program product for real time media production
MXPA02002032A (es) 1999-08-27 2003-05-19 Ligand Pharm Inc Compuestos moduladores del receptor de androgeno y metodos.
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1212322A2 (de) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituierte-6-trifluoromethyl-9-pyrido[3,2-g]chiolinverbindungen als androgen rezeptormodulatoren
EP1216221A2 (de) * 1999-09-14 2002-06-26 Ligand Pharmaceuticals Incorporated Rxr modulatoren mit verbessertem pharmakologischem profil
JO2178B1 (en) 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
CN1311232A (zh) * 2000-03-02 2001-09-05 上海博德基因开发有限公司 一种新的多肽——人视网膜瘤蛋白22和编码这种多肽的多核苷酸
CA2401491C (en) 2000-03-03 2011-07-05 Kyowa Kirin Co., Ltd. Ccr4-binding antibody and diagnostic and therapeutic uses thereof
EP1273008A2 (de) * 2000-03-31 2003-01-08 Parkervision, Inc. Verfahren, system und rechnerprogrammprodukt zur vollständigen integration von nachrichten und automatisierung in einer echtzeit videoproduktionsumgebung
EP1478384A2 (de) * 2001-06-11 2004-11-24 Ludwig Institute For Cancer Research Verfahren zur verbesserung der überlebensrate von dopaminsezernierenden zellen
CA2458627C (en) 2001-08-31 2013-09-10 Kyowa Kirin Co., Ltd. Human cdr-grafted antibody and antibody fragment thereof
ES2284959T3 (es) * 2001-10-30 2007-11-16 Nektar Therapeutics Al, Corporation Conjugados polimericos solubles en agua de acido retinoico.
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
EP1527774A1 (de) * 2003-11-03 2005-05-04 Basilea Pharmaceutica AG Neue Zubereitungsform für retinoidhaltige Weichgelatinekapseln
US9050310B2 (en) * 2004-06-25 2015-06-09 Minas Theodore Coroneo Treatment of ocular lesions
EP1771163A1 (de) * 2004-07-29 2007-04-11 Werner Bollag Behandlung von multipler sclerose mit rxr-antagonisten
EP1621191A1 (de) * 2004-07-29 2006-02-01 Werner Bollag Behandlung von Entzündungserkrankungen mit RXR-Antagonisten
EP1799812A4 (de) 2004-09-16 2009-09-09 Gamida Cell Ltd Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen
US20060204474A1 (en) * 2005-02-25 2006-09-14 Coroneo Minas T Treatment of epithelial layer lesions
US20070049579A1 (en) * 2005-03-04 2007-03-01 Ryozo Nagai Medicament having neovascularization promoting action
AU2006308168A1 (en) * 2005-10-25 2007-05-03 Werner Bollag RXR agonists and antagonists, alone or in combination with PPAR ligands, in the treatment of metabolic and cardiovascular diseases
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
WO2008137488A1 (en) * 2007-05-01 2008-11-13 Purdue Research Foundation Methods for controlling inflammatory and immunological diseases
WO2011103141A1 (en) 2010-02-16 2011-08-25 Ams Research Corporation Bioabsorbable mesh for surgical implants
BR112014020119A2 (pt) 2012-02-13 2020-10-27 Gamida-Cell Ltd cultura de células-tronco mesenquimais
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
AU2015237779A1 (en) 2014-03-28 2016-10-20 Implant B Ltd. Renewable dental implant
JP6836829B2 (ja) * 2014-08-04 2021-03-03 日東電工株式会社 核内受容体リガンドを含む免疫誘導促進用組成物及びワクチン医薬組成物
US11045441B2 (en) 2015-10-13 2021-06-29 Wisconsin Alumni Research Foundation Use of retinoic acid and analogs thereof to treat central neural apneas
CN108247233B (zh) * 2017-12-13 2020-10-20 上海华峰铝业股份有限公司 碱洗无钎剂或真空钎焊板的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176571A (en) * 1876-04-25 Improvement in filters and processes for cleaning the same
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5925546A (en) * 1987-11-02 1999-07-20 Chiron S.P.A. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
US5601831A (en) * 1989-03-09 1997-02-11 Praxis Biologics, Inc. Vaccines for nontypable Haemophilus influenzae
FR2676052B1 (fr) 1991-05-02 1994-04-29 Cird Galderma Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique.
CA2093577C (en) * 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
US5612356A (en) * 1992-12-28 1997-03-18 Eisai Co., Ltd. Heterocycle-containing carbonic acid derivatives
CA2138000A1 (en) * 1994-01-03 1995-07-04 John E. Starrett, Jr. Retinoid-like compounds
FR2719041B1 (fr) 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés polyéniques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
AU2823395A (en) * 1994-06-07 1996-01-04 Sri International Novel compounds useful in modulating gene expression of retinoid responsive genes and/or having anti-ap-1 activity
PL180048B1 (en) 1994-08-10 2000-12-29 Fhoffmann La Roche Ag Ligands of retinic acid x-receptors
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
DE69604713T2 (de) 1995-02-24 2000-06-21 F. Hoffmann-La Roche Ag, Basel Retinoide
FR2733684B1 (fr) * 1995-05-03 1997-05-30 Cird Galderma Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
WO1997012853A1 (en) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US6685949B1 (en) * 1998-01-13 2004-02-03 The United States Of America As Represented By The Department Of Health & Human Services Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
AU6955898A (en) * 1997-04-11 1998-11-11 Bristol-Myers Squibb Company Retinoid antagonists and uses thereof

Also Published As

Publication number Publication date
US6133309A (en) 2000-10-17
CN1301156A (zh) 2001-06-27
ES2270537T3 (es) 2007-04-01
ZA9810122B (en) 1999-05-12
KR20030062452A (ko) 2003-07-25
US20030176420A1 (en) 2003-09-18
DE69835441D1 (de) 2006-09-14
EP1030662B1 (de) 2006-08-02
AR017590A1 (es) 2001-09-12
AU1560499A (en) 1999-05-31
AU749810B2 (en) 2002-07-04
WO1999024024A2 (en) 1999-05-20
CN1511519A (zh) 2004-07-14
KR20040031107A (ko) 2004-04-09
KR20010032000A (ko) 2001-04-16
CA2307879A1 (en) 1999-05-20
JP3704471B2 (ja) 2005-10-12
EP1030662A2 (de) 2000-08-30
US6610742B1 (en) 2003-08-26
KR100440836B1 (ko) 2004-07-19
CA2307879C (en) 2009-12-22
JP4157107B2 (ja) 2008-09-24
DE69835441T2 (de) 2007-08-02
JP2001522797A (ja) 2001-11-20
US20060183737A1 (en) 2006-08-17
TR200001228T2 (tr) 2001-01-22
KR20040032963A (ko) 2004-04-17
BR9814957A (pt) 2000-10-03
JP2005281313A (ja) 2005-10-13
US20050227967A1 (en) 2005-10-13
JP2006298903A (ja) 2006-11-02
WO1999024024A3 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
ATE334673T1 (de) Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
ATE286510T1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
DE69735763D1 (de) Intravaskuläre verabreichung von medikamenten durch elektroporation
DE69631138D1 (de) Abgabe von sauerstoffübersättigten, physiologischen lösungen
DE69938299D1 (de) Lokale abgabe von arzneimitteln
IT1236831B (it) Apparecchio per il trattamento dell'intestino in particolare per enteroclisma
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
ATE239011T1 (de) Neuartige form von s-omeprazol
DE69500089D1 (de) Behandlung von Geflügel
DE69325373D1 (de) Therapeutische ultraschallzahnbürste
DE69329764D1 (de) Neues kosmetisches präparat
DE69508112D1 (de) Reinigung von 1,3- propandiol
DE69430903D1 (de) Behandlung von periodontitis mit misoprostol
DE69316203D1 (de) Elektrochemische behandlung von oberflächen
ATE292975T1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE69731646D1 (de) Verabreichung von nukleinsäurepartikeln
IT1291366B1 (it) Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale
DE59915061D1 (de) Herstellung von strukturierten elektroden
DE69133390D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten in der behandlung von hämorragischem schlaganfall
DE69619051D1 (de) Behandlung von Füllstoffen mit Oxasilacycloalkanen
NO996492L (no) Oppløsningsdoseringsformer av sertralin innkapslet i gelatin
NO980375D0 (no) Humant MP52 Arg protein
IT1224636B (it) Esteri penem 6 sostituiti come agenti antinfiammatori e antidegenerativi.
DE69522685D1 (de) Behandlung von blut-plasma
DE69802300D1 (de) Behandlung von schädlichen flüssigkeiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1030662

Country of ref document: EP

EEIH Change in the person of patent owner